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Background: A quadrivalent influenza vaccine (QIV) includes two A strains (A/H1N1, A/H3N2) and two B
lineages (B/Victoria, B/Yamagata). The presence of both B lineages eliminate potential B lineage mismatch
of trivalent influenza vaccine (TIV) with the circulating strain.
Methods: Electronic database searches of Medline, Embase, Cochrane Central Register of Controlled Trials
(CCRCT), Scopus and Web of Science were conducted for articles published until June 30, 2015 inclusive.
Articles were limited to randomised controlled trials (RCTs) in adults using inactivated intramuscular
vaccine and published in English language only. Summary estimates of immunogenicity (by seroprotec-
tion and seroconversion rates) and adverse events outcomes were compared between QIV and TIV, using
a risk ratio (RR). Studies were pooled using inverse variance weights with a random effect model and the
I2 statistic was used to estimate heterogeneity.
Results: A total of five RCTs were included in the meta-analysis. For immunogenicity outcomes, QIV had
similar efficacy for the three common strains; A/H1N1, A/H3N2 and the B lineage included in the TIV. QIV
also showed superior efficacy for the B lineage not included in the TIV; pooled seroprotection RR of 1.14
(95%CI: 1.03–1.25, p = 0.008) and seroconversion RR of 1.78 (95%CI: 1.24–2.55, p = 0.002) for B/Victoria,
and pooled seroprotection RR of 1.12 (95%CI: 1.02–1.22, p = 0.01) and seroconversion RR of 2.11 (95%CI:
1.51–2.95, p < 0.001) for B/Yamagata, respectively. No significant differences were found between QIV
and TIV for aggregated local and systemic adverse events within 7 days post-vaccination. There were
no vaccine-related serious adverse events reported for either QIV or TIV. Compared to TIV, injection-
site pain was more common for QIV, with a pooled RR of 1.18 (95%CI: 1.03–1.35, p = 0.02).
Conclusion: In adults, inactivatedQIVwas as immunogenic as seasonal TIV,with equivalent efficacy against
the shared three strains included in TIV, and a superior immunogenicity against the non-TIV B lineage.
 2016 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
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Influenza is a major cause of disease burden globally.
Vaccination is the most effective intervention available to prevent
influenza infection [1]. Both seasonal and pandemic influenza
infections affect all ages; however, children and the older people
have the highest incidence, morbidity and mortality from the
infection [2,3].
A bivalent inactivated influenza vaccine was widely used from
1944 until the trivalent vaccine (containing A/H1N1, A/H3N2 and
one B lineage) was introduced in 1978 [4]. Since then, trivalent influ-
enza vaccine (TIV), either inactivated or live-attenuated, has been
the leading prevention strategy against influenza. Current seasonal
influenza strains in circulation include two influenza A subtypes
(A/H1N1 and A/H3N2), and two antigenically and genetically dis-
tinct B lineages (B/Victoria and B/Yamagata). Both influenza A sub-
types and both B lineages co-circulate, with relative incidence of
each subtype and lineage varying widely by season and geographic
region [5,6]. Every year, inclusion of three influenza strains is
carefully selected for TIV by the World Health Organisation (WHO)
for the upcoming influenza season and recommended for use for
northern and southern hemisphere influenza vaccines [7]. TIV
includes both A strains and one lineage of B (either B/Victoria or B/
Yamagata), and thus mismatch of the vaccine B lineage included in
the seasonal TIV has occurred in 25% of seasons across global
regions, on average [8].
A meta-analysis of TIVs found protective efficacy of 59% for
inactivated TIV in adults and 83% for live-attenuated vaccine in
children (6 months to 7 years) [9]. However, efficacy of vaccine
varies by age, individual immune response and the degree of
cross-protection of the vaccine B lineage against the alternate
lineage [10–13].
In 2012, a newly available quadrivalent influenza vaccine (QIV)
that includes both B lineages was recommended for use by the
WHO to improve protection against influenza B. Randomised con-
trolled trials (RCTs) comparing the QIV with TIV showed that QIV
was immunogenic for both A strains and B lineages in adults and
children [14–18].
Studies have documented that the use of QIV could result in
lower population incidence of influenza infection and its
complications [19–21]. A United States (US) study of the
2001/2002–2011/2012 influenza seasons estimated that on
average at least 30,000 cases, 3500 hospitalisations and 700 deaths
could have been prevented in their population through use of QIV
over TIV [22]. Another modelling study from Germany concluded
that QIV could have prevented 11.2% of influenza B infections
(395,000 infections per annum in the population) caused by vac-
cine B lineage mismatch [23].
RCTs of QIV have shown promising results against influenza B
[16,18,24]. To our knowledge, no meta-analysis of RCTs in adults
has yet been published. Thus, we performed a systematic
review and meta-analysis of RCTs to determine the
immunogenicity and safety of inactivated QIV compared to TIV in
healthy adults.2. Methods
Electronic database searches of Medline, Embase, Scopus, Web
of Science, and Cochrane Central Register of Controlled Trials
(CCRCT) were conducted for published articles from the earliest
available dates reported in the databases to June 30, 2015 inclu-
sive. The search was limited to human studies and randomised
controlled trials (RCTs), and studies published in English language
only. The inclusion criteria for study selection were studies with
immunogenicity and safety outcomes of intramuscular administra-
tion of inactivated QIV compared to inactivated TIV in adults aged
18 years and over. We excluded animal studies, experimental and
observational epidemiologic studies. Studies that compared
quadrivalent vaccine to placebo or any vaccines other than TIV,
studies conducted in children and immunocompromised people,
studies with live-attenuated or adjuvant quadrivalent vaccines,
and RCTs comparing QIV and TIV using other routes of vaccine
administration were also excluded in our meta-analysis. Both
QIV and TIV vaccines used 15 lg haemagglutinins per strain, and
were given as 0.5 mL dose intramuscularly.
2.1. Data extraction
Two independent reviewers (AMM and AAC) selected and
reviewed the articles and extracted the data by the selection crite-
ria. If the data were not available, we calculated the required data
from the percentages reported in the study accordingly. Disagree-
ments between the reviewers were resolved by consensus. One
study also examined low-dose adjuvant QIV and TIV vaccines in
comparison to standard 15 lg inactivated vaccines [24]. However,
for data consistency amongst studies, we did not include data from
the low-dose adjuvant vaccines in the meta-analysis.
2.2. Outcome measures
Immunogenicity was the primary outcome and the secondary
outcome was the number of adverse events, compared between
QIV and TIV. Serological outcome assessments were determined
by haemagglutination inhibition (HI) assay and immune responses
were measured at 21 day post-vaccination. Studies were also anal-
ysed for older adults (aged > 60 years) if data were available. All
studies were considered for the pooled estimates if relevant results
were available.
2.2.1. Immunogenicity
Immunogenicity was measured by means of seroprotection rate
(SPR) and seroconversion rate (SCR), and was assessed for each of
four strains: A/H1N1, A/H3N2, B/Victoria and B/Yamagata, both
in the QIV and TIV groups. The seroprotection rate was defined
as the percentage of participants with a HI titreP40, and the sero-
conversion rate was defined as the percentage of participants with
either a pre-vaccination HI titre <10 and a post-vaccination HI titre
P40 or a pre-vaccination HI titreP10 and aP4-fold increase in HI
titre after vaccination. The efficacy of QIV compared to TIV is a
4094 A.M. Moa et al. / Vaccine 34 (2016) 4092–4102comparison of the three strains included in both vaccines and the
efficacy for an additional strain not included in the TIV vaccine.
The studies included either one TIV vaccine arm only or would
include two different TIV vaccine arms containing each B lineage
separately. Therefore QIV was compared to two types of TIV vac-
cine (either B/Victoria or B/Yamagata) with studies contributing
either one or both comparisons. We report comparisons of seropro-
tection and seroconversion for QIV versus TIV in the meta-analysis.
For immunogenicity outcome, if the required study data were not
provided for the whole study, then the data were extracted only
from the sub-groups available in the study.
2.2.2. Adverse events
The number or percentage of subjects who experienced vaccine
adverse events within 7 days post-vaccination was extracted from
the studies. The proportion of adverse events were analysed by
local and systemic events. For comparison with QIV, adverse events
from TIV-B/Victoria and TIV-B/Yamagata groups were combined as
pooled TIV by adding together the number of adverse events and
the total number of participants. This was required as one of the
studies reported adverse events pooled across the two TIV arms
so analysis by the two TIV types was not possible. Local reactions
were pain, redness and swelling, and systemic events were fatigue,
headache, myalgia and fever. The most frequently reported local or
systemic events in QIV and TIV were also assessed. Serious adverse
events (SAEs) and deaths related to vaccines and adverse events of
special interest such as Guillain–Barré syndrome, Bell’s palsy, optic
neuritis and encephalitis were reviewed in the study.
2.3. Statistical analysis
Study specific risk ratios (RR) and their 95% confidence intervals
(CI) were estimated and plotted in forest plots for seroprotection,172 records retrieved 
through electronic 
database searches
107 records excluded 
after screening of 
titles and abstracts
65 records identified for 
inclusion
19 full-text articles 
assessed for eligibility 
after removal of 
duplicates
14 full-text articles excluded; 
8 studies conducted in 
children, 3 studies used live-
attenuated QIV vaccine, 2 
studies with ID vaccine, 1 
non-RCT study 
5 studies included in
the review and
meta-analysis
Fig. 1. Flow diagram for study selection. QIV: quadrivalent influenza vaccine, ID:
intradermal, RCT: randomised controlled trial.seroconversion and adverse events. These risk ratios compared pro-
portions of subjects receiving QIV versus thosewho received TIV for
each of the outcomes above. Estimates were pooled using inverse
variance weighting and random effects to allow for between study
heterogeneity. The I2 statistic, which estimates the percentage of
total variation across studies due to heterogeneity, was used to
assess the level of heterogeneity [25]. All analyses were conducted
in Review Manager (version 5.3) [26]. P-values < 0.05 were
considered to be statistically significant in the meta-analysis.
2.4. Sensitivity analysis
A sensitivity analysis was conducted to investigate the influ-
ence of length of follow-up for reporting adverse events. We
excluded a study that reported adverse events up to 3 days post-
vaccination [16], as all other studies reported adverse events up
to 7 days after vaccination. We then reported the overall pooled
estimate RR for the adverse events after removal of the study to
see if the results changed substantially.
2.5. Quality of included studies
The quality of studies was investigated independently by two
authors (AMM and AAC) using the Cochrane’s risk of bias assess-
ment [27]. Studies were assessed for potential sources of bias
according to key domains such as selection bias, performance bias,
detection bias, attrition bias, and reporting and other bias. Each
trial was reviewed for presence of random sequence generation;
allocation concealment; blinding of participants, investigators
and outcome assessors; and method of reporting in the trial, and
described as low, unclear or high risk of bias appropriately. We
used PRISMA checklist items in accordance with the PRISMA state-
ment, to report the study’s findings in the meta-analysis [28].
3. Results
In all, 172 articles were retrieved from the initial search. After
review of titles and abstracts, and removal of duplicates, 19 articles
remained for full review. The flow diagram of study selection is
shown in Fig. 1. Five RCTs met the inclusion criteria and were
included in the final review and meta-analysis. A minimum of
4623 and 4342 participants were included in the meta-analyses
for QIV versus TIV including B/Victoria (TIV-B/Victoria) and QIV
versus TIV including B/Yamagata (TIV-B/Yamagata) for the
immunogenicity outcome analyses [15,16,18,24,29]. The charac-
teristics of the included RCTs are described in Table 1.
Amongst the included studies, one was double blind [18], three
[15,24,29] were partially blinded and one was an open-label trial
[16]. In general, studies showed low risk of bias. Most studies used
‘intention-to-treat’ (ITT) for the adverse events outcome analysis;
however, studies used ‘per-protocol analysis set’ for the immuno-
genicity outcome. Attrition bias was rated as high risk due to
incomplete outcome assessment in the meta-analysis, as immuno-
genicity was assessed using ‘per-protocol analysis’ in the included
RCTs. Studies showed approximately less than 3% of withdrawals
and lost to follow-up, and only one study had approximately 15%
drop-outs in the TIV group only. Studies reported adequately for
participants’ selection and performance method, and outcomes
were assessed appropriately, therefore there were low risks for
selection bias, performance and detection bias. The quality of
included studies is summarised in the appendix Fig. A1.
3.1. Immunogenicity
A total of five studies were included for the immunogenicity
outcome in the meta-analysis. No significant differences were
Table 1
Study characteristics of included studies.
Study (year), Ref. Country Type of study Study period Age (year);
Mean age,
QIV vs TIV
Total number
of subjects
randomized/
vaccinated (N)
Intervention
vaccine (QIV)
Vaccine strains in QIV Vaccine strains in TIV Vaccine
manufacturer
Beran et al. [24] Czech Republic Phase I/II,
single-blind
July 2008–January
2009
18–60; 38.6 y
vs 37.4 y
420 QIV (inactivated
split-virion) or
(non-adjuvanted
or low-dose
adjuvanted [LD
QIV-AS])
A/Solomon Islands/03/2006
(H1N1), A/Wisconsin/67/2005
(H3N2), B/Malaysia/2506/
2004 (B/Vic), B/Jiangsu/10/
2003 strain (B/Yam)
2007–2008 TIV or LD TIV-AS
(low-dose adjuvated TIV);
H1N1, H3N2, B/Malaysia/
2506/2004 (B/Vic)
GlaxoSmithKline
(GSK)
Greenberg et al.
[16]
USA Phase II,
open-label
October–December
2009
18 and over;
56.7 y vs 55 y
590 QIV (Inactivated) A/Brisbane/59/2007 (H1N1),
A/Uruguay/716/2007 (H3N2),
B/Brisbane/60/2008 (B/Vic),
B/Florida/04/2006 (B/Yam)
2009–2010 TIV: H1N1, H3N2,
B/Brisbane/60/2008 (B/Vic);
2008–2009 TIV: H1N1, H3N2,
B/Florida/04/2006 (B/Yam)
Sanofi Pasteur,
Swiftwater, PA,
USA
Kieninger et al.
[15]
Germany,
Romania, Spain,
Korea, Taiwan,
USA
Phase III,
partially-blind
October 2010–June
2011
18 and over;
57.9 y vs
58.1 y
4656 QIV (inactivated
split-virion)
A/California/7/2009 (H1N1),
A/Victoria/210/2009 (H3N2),
B/Brisbane/60/2008 (B/Vic),
B/Brisbane/3/2007 (B/Yam)
TIV-Vic: H1N1, H3N2, B/
Brisbane/60/2008 (B/Vic);
TIV-Yam: H1N1, H3N2, B/
Brisbane/3/2007 (B/Yam)
GlaxoSmithKline
(GSK), Dresden,
Germany
Pepin et al. [29] France, Germany Phase III,
double-blind
October 2011–June
2012
18 and over;
55.1 y vs
55.1–56 y
1565 QIV (inactivated) A/California/07/2009 (H1N1),
A/Victoria/210/2009 (H3N2),
B/Brisbane/60/2008 (B/Vic),
B/Florida/04/2006 (B/Yam)
2010–2011 TIV (licensed): A/
H1N1, A/H3N2, B/Brisbane/
60/2008 (B/Vic);
investigational TIV: A/H1N1,
A/H3N2, B/Florida/04/2006
(B/Yam)
Sanofi Pasteur
Tinoco et al. [18] Canada, Mexico,
USA
Phase III,
double-blind
2010–2011 18 and over;
50 y vs 50 y
1703 QIV (inactivated
quadrivalent split-
virion)
A/H1N1 (A/California/7/
2009), A/H3N2 (A/Victoria/
210/2009), B/Brisbane/60/
2008 (B/Vic), B/Florida/4/
2006 (B/Yam)
2010–2011 TIV (Inactivated):
A/H1N1 (A/California/7/
2009), A/H3N2 (A/Victoria/
210/2009), B/Brisbane/60/
2008 (B/Vic) or B/Florida/4/
2006 (B/Yam)
FluLavalTM
GlaxoSmithKline,
Quebec, Canada
QIV: quadrivalent influenza vaccine; TIV: trivalent influenza vaccine; vs: versus; H1N1 or A/H1N1: influenza A subtype; H3N2 or A/H3N2: influenza A subtype; B/Vic: B/Victoria lineage; B/Yam: B/Yamagata lineage.
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Fig. 2a. Seroprotection rate (SPR) at day 21 post-vaccination, QIV versus TIV in adults (A strains). (SPR is defined as the percentage of participants with a HAI titres P40).
4096 A.M. Moa et al. / Vaccine 34 (2016) 4092–4102observed for three common strains (2As and 1B of TIV vaccine
lineage) between QIV and TIV. Significant heterogeneity was
observed for immunogenicity outcomes in the meta-analysis.
Figs. 2a and 2b show forest plots of the risk ratios for the
seroprotection rate for each A and B strain, comparing QIV with
either TIV-B/Victoria or TIV-B/Yamagata, respectively. The pooled
seroprotection RRs for A/H1N1, and A/H3N2 were 1.0 (95%CI:
0.98–1.02), and 1.0 (95%CI: 0.99–1.01) for TIV-B/Victoria, and 1.0
(95%CI: 0.98–1.02) and 1.0 (95%CI: 0.97–1.02) for TIV-B/Yamagata
(Fig. 2a).
When comparing QIV for the B lineage in the TIV, the pooled
seroprotection RRs were 1.0 (95%CI: 0.99–1.01, p = 0.43) for
B/Victoria and 1.0 (95%CI: 0.99–1.0, p = 0.52) for B/Yamagata
lineage. QIV showed superior seroprotection for the B lineage not
included in the TIV, with SPR RRs of 1.14 (95%CI: 1.03–1.25,
p = 0.008) for B/Victoria and 1.12 (95%CI: 1.02–1.22, p = 0.01) for
B/Yamagata as shown in Fig. 2b.
Similarly, seroconversion rates are described in Figs. 3a and 3b.
Pooled SCR RRs were 1.01 (95%CI: 0.97–1.06) for A/H1N1 and 0.98(95%CI: 0.89–1.08) for A/H3N2 for TIV-B/Victoria. For the compar-
ison of QIV with TIV-B/Yamagata, RRs were 1.00 (95%CI: 0.93–1.07)
and 0.99 (95%CI: 0.93–1.04) for A/H1N1 and A/H3N2, respectively
(Fig. 3a).
When comparingQIV for theB lineage in the TIV, thepooled sero-
conversion RRs were 1.05 (95%CI: 0.99–1.12, p = 0.11) for B/Victoria
and 1.08 (95%CI: 0.99–1.18, p = 0.10) for B/Yamagata. QIV showed
superior seroconversion for the B lineage not included in the TIV,
with SCR RRs of 1.78 (95%CI: 1.24–2.55, p = 0.002) for B/Victoria
and 2.11 (95%CI: 1.51–2.95, p < 0.001) for B/Yamagata (Fig. 3b).
3.2. Immunogenicity in persons aged > 60 years
Data for this age group were available from 2 studies [16,29],
and thus analysed separately in the meta-analysis. For A strains,
QIV had similar immune responses to TIV (data not shown). QIV
induced superior immunogenicity to the B lineage not included
in the TIV, with SPR RR of 1.16 (95%CI: 1.0–1.34, p = 0.05), for
B/Yamagata, and RR of 1.19 (95%CI: 0.88–1.61, p = 0.27) for
Fig. 2b. Seroprotection rate (SPR) at day 21 post-vaccination, QIV versus TIV in adults (B lineages).
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for the B lineage not included in the TIV. SCR RR were 2.70
(95%CI: 1.12–6.51, p = 0.03) and 2.78 (95%CI: 2.11–3.66, p < 0.001)
for B/Victoria and B/Yamagata, respectively. For RRs of seroprotection
and seroconversion rate, no significant differences were found
between QIV and the B lineage in the TIV (data not shown).
3.3. Adverse events
Three studies [16,24,29] reported the total number of subjects
with one or more local and the number with one or more systemic
adverse event within 7 days post-vaccination, and pooled RRs were
determined for the two vaccine groups. One study reported
adverse events within 3 days post-vaccination [16]. The largest,
multicentre trial was not included in this analysis because adverse
events were not categorised into local or systemic events [15].
There were no significant differences in the occurrence of any
local or systemic events, with pooled RRs of 1.16 (95%CI:
0.96–1.40, p = 0.12) and 1.07 (95%CI: 0.95–1.20, p = 0.25), respec-
tively, comparing QIV with combined TIV containing either or bothB lineages (Fig. 4). Evidence of heterogeneity was seen for local
reactions. Injection-site pain was the most frequently reported
solicited local event, and fatigue, headache and myalgia were com-
monly reported solicited systemic events among the studies. From
the available study data, pooled RRs for each of pain, headache,
fatigue, and myalgia were estimated. There was a higher incidence
of injection-site pain with QIV, with a pooled RR of 1.18 (95%CI:
1.03–1.35, p = 0.02) (Appendix, Fig. A2). There were low occurrence
of redness and swelling in both vaccine groups and were reported
less than 6–8% across the studies.
QIV did not show any significant differences in frequently
reported systemic adverse events such as headache, fatigue and
myalgia when compared to TIV (data not shown). Studies reported
the number of participants experiencing fever. Fever had very low
incidence in both QIV and TIV groups, ranging from 0.0% to 1.0% in
QIV and 0.0% to 1.1% in TIV, respectively. One study reported one
immediate (within 30 min) unsolicited adverse event with QIV of
grade 2-nausea, and which was considered as treatment-related
by the investigators [29]. Studies also reported that both solicited
local and systemic adverse eventswere transient in nature, and they
Fig. 3a. Seroconversion rate (SCR) at day 21 post-vaccination, QIV versus TIV in adults (A strains). (SCR is defined as the percentage of participants with either
a pre-vaccination HAI titre <10 and a post-vaccination HAI titre P40 or a pre-vaccination HI titre P10 and a P4-fold increase in HI titre after vaccination).
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unsolicited adverse events were comparable between QIV and TIV.
Unsolicited adverse events and serious adverse events (SAEs) were
followed up at 21 days or 6 months after vaccination. During
21 days post vaccination, frequently reported unsolicited adverse
eventswere nasopharyngitis, cough, andoropharyngeal pain among
QIV and TIV groups [15,16,18]. SAEs were comparable between QIV
and TIV; ranged from 0.5% to 2.8% in QIV and 0.6% to 2.6% in TIV
group [15,18,29]. However, none of these SAEs were reported as
vaccine-related events by the investigators. There were no reports
of vaccine-related deaths or adverse events of special interest.
While we could not include the study by Kieninger et al. [15]
in the meta-analysis of one or more local or systemic adverse
events, the number of subjects enrolled in that study was larger
than the combined number of subjects in our meta-analysis of
the remaining studies. The Kieninger et al. study did not find
any significant difference in any single adverse event, including
injection-site pain [15].3.4. Sensitivity analysis
We performed a sensitivity analysis for the adverse events out-
come, to determine the impact on the duration of follow-up for
adverse events, as one study [16] reported the local and systemic
adverse events at day 3 post-vaccination rather than 7 days. The
pooled RRs for adverse events were similar after removal of the
particular study (data not shown).
4. Discussion
To our knowledge, this is the first meta-analysis comparing
immunogenicity and safety of inactivated QIV against TIV in the
adult population. The meta-analysis confirms that, in adults, the
inactivated QIV used in the studies had equivalent efficacy against
the shared three strains between the two vaccines and statistically
significant superior efficacy against B lineage not included in the
TIV. QIV provided a 14% (95%CI: 3–25) and 78% (95%CI: 24–155)
Fig. 3b. Seroconversion rate (SCR) at day 21 post-vaccination, QIV versus TIV in adults (B lineages).
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compared to TIV for B/Victoria, and a 12% (95%CI: 2–22) and
111% (95%CI: 51–195) higher seroprotection and seroconversion
rate for B/Yamagata, respectively. The immunogenicity of the three
strains common to both vaccines was not compromised. In
addition, QIV induced statistically significant higher seroconver-
sion rates for older adults (>60 years) against the non-TIV B lin-
eage. Overall QIV would deliver improved protection and reduce
the burden of influenza B infections in the population when there
is a mismatch between the circulating and TIV B lineage.
Our meta-analysis showed a comparable safety profile between
QIV and TIV. However, QIV had slightly increased frequency of
injection-site pain compared to TIV. While there was no statisti-
cally significant difference in overall rate of adverse events, a
non-randomised observational post-marketing surveillance study
conducted during the 2015 influenza season in Western Australia
showed a small difference in the low rate of local reactions
(injection- site pain or swelling) following QIV (6.9%) compared
with TIV (4.2%) among healthcare professionals [30]. Differencesin adverse events rates may be due to differences in vaccine formu-
lation by different vaccine manufactures, and the addition of an
extra antigen in QIV [30]. QIV contains an additional 15 lg of influ-
enza antigens compared to TIV, giving a total 60 lg. However, our
meta-analysis did not find any significant differences in the sys-
temic events, headache and myalgia between the two vaccines.
Fever was reported in studies but occurred at very low rates. Trials
reported that the rate of both local and systemic adverse events
were transient and short-lived, and resolved within 1–3 days in
both vaccine groups. No vaccine-related SAEs or deaths were asso-
ciated with the vaccines. Although QIV had a slight increase in local
reaction (injection-site pain) compared to TIV, the potential benefit
of QIV is considered to be greater with regards to improved protec-
tion from the infection in the population.
We included only randomised controlled trials in the
meta-analysis, thus limiting sources of potential bias in the study.
Despite using ‘‘per-protocol analysis” for the immunogenicity out-
come, all studies appropriately reported the number of participant
withdrawals and loss to follow-up, and withdrawal rates were
Fig. 4. Adverse events during 0–7 days post vaccination, QIV versus pooled TIV (TIV groups combined (TIV-B/Victoria & TIV-B/Yamagata); local- number of subjects with local
adverse events; systemic-number of subjects with systemic adverse events).
Fig. A1. Risk of bias summary for each included study.
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bias is unlikely to be important. In the meta-analysis, there was
evidence of significant heterogeneity among the studies. We
applied a random effects model to allow for this. Heterogeneity
in study findings may have been due to variation in age of study
subjects, being conducted in different countries with varied influ-
enza seasons, using different vaccine manufacturers, and variation
in HI responses of subjects due to different historical exposures to
natural infection or vaccination. A small but statistically significant
difference in local reaction between the two vaccines that the
meta-analysis revealed highlights the limited statistical power of
individual RCTs, which individually reported a similar reactogenic-
ity profile. Our meta-analysis provides greater statistical power,
due to the larger sample size, to detect smaller difference in
adverse and rarer event rates compared to individual RCTs.
Does the immunogenicity reported in these studies translate
into efficacy or clinical protection against infection? The included
studies reported HI antibody titre responses by means of seropro-
tection and seroconversion rates. The relationship between HI anti-
body titre and clinical protection is well established, and is
frequently used for assessment of vaccine efficacy. A HI titre of
P40 has been reported as providing 50% protection against infec-
tion by influenza [31]. This association is also supported by a mod-
elling study, finding that, regardless of vaccination status of
individual and the viral strains (either A or B), a positive and statis-
tically significant relationship exists between HI antibody titre and
clinical protection against influenza infection [32]. RCTs included
in our meta-analysis [15,16,18,24,29] reported that QIV demon-
strated at least comparable or a higher level of seroprotection
and seroconversion rates than TIV, and also met the criteria out-
lined by the Center for Biologics Evaluation and Research (CBER),
and Committee for Human Medicinal Products (CHMP) for the
licensure of influenza vaccine from US and Europe [33,34].
Historically, it is reported that there was little or no cross-
protection for infection by one B lineage against the other in
immunologically naïve animals (ferrets) and in human studies
[35–37]. In contrast, significant cross-reactivity between the two
B lineages was reported in a study of middle-aged and elderly
adults by the trivalent vaccine [38]. Other studies also reported
an evidence of cross-reactive responses following influenza vacci-
nation with alternate B lineages [39,40]. A meta-analysis of RCTsof TIV by Tricco et al. [41] showed vaccine efficacy of 52% and
77% for mismatched andmatched B lineages in adults, respectively,
providing that there is a cross-reactivity of 67.5% by TIV between
the two B lineages. Variations in cross-reactivity among individuals
or in the population can be explained by antigenic variability of
influenza strains as well as previous exposure of influenza infec-
tion or vaccination [38,40].
To date, fewmodelling studies reported the cost-effectiveness of
QIVover TIV [22,42–46]. A studybyClements et al. [46] reported that
Fig. A2. Adverse event analysis for injection-site pain during 0–7 days post vaccination, QIV versus TIV. (Greenberg, 2013 – adverse events were followed up within 3 days after
vaccination).
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of direct medical and indirect costs saved were about by US$111.6
million and US$218.7 million, respectively, with QIV compared to
TIV using a base-casemodel. In general, QIV offers improved protec-
tion from the unmatched influenza B infections; however switching
of QIV into routine immunisation programs, would require proper
cost-effectiveness analyses studies comparing incremental cost-
effectiveness of QIV over TIV. Costs associated with influenza
infections are substantial and both direct and indirect costs are to
be considered in theeconomicburdenof thedisease. The importance
of appropriatemodelling studies in estimating the costs and benefits
of using QIV over TIV, and by per country-level consideration, when
switching between two vaccination programs in the population has
been pointed out [47]. Other factors such as productivity and cost of
vaccine should also be considered for utilisation of QIV extensively.
There are limitations in the current study. Our meta-analysis is
limited to non-adjuvant formulation and inactivated vaccines only
and thus our results may not apply for other vaccine formulations.
We only studied RCTs in the adult population and our findings can-
not be generalised to children. In elderly people, immune responses
to vaccination are complex and sophisticated due to immunosenes-
cence, and had less antibody responses compared to adults [48]. Our
findings in older adults may be limited as there were only two RCTs
of older adults where data were applicable in the meta-analysis
[16,29]. In general, HI antibody responses were assessed at 21 days
post-vaccination. One trial described the antibody responses at
6 months, and found that HI titres were lower at 6 months than at
21 days and remained higher than baseline levels. Immunogenicity
for B lineages was higher than A strains at 6 months [18]. Persistent
of long-term vaccine efficacy should also be explored further for QIV
in particular with B lineages. Another limitation in our meta-
analysis is that surrogate outcomes (laboratory values) were
assessed for the efficacy of vaccine, and thus these findings may
not reflect actual clinical efficacy or effectiveness at a population
level. Last, our studymayhave been subject to language, publication
or database bias. We did not assess for publication bias due to lim-ited number of studies included in the meta-analysis. Nonetheless,
we believed that the meta-analysis provided a larger sample size in
the summary estimates, thus it’s unlikely to alter our results.
5. Conclusion
In adults, inactivated QIV induced comparable immune
responses to TIV for A strains and the B lineage common to both
QIV and TIV, and showed statistically significant higher immuno-
genicity for the B lineage not included in the comparison TIV. This
meta-analysis demonstrates that QIV compared to TIV, was tolera-
ble and immunogenic to all four strains. The use of QIV would
reduce undesirable mismatched B infections and offer potential
advantages over TIV by reducing influenza-related morbidity and
mortality in the adult population. Few studies examined older
adults specifically and thus more research is needed in this age
group. In addition, future studies of vaccine safety and cost-
effectiveness of QIV might be useful.
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